56222-08-3

Usage

Uses

Used in Pharmaceutical Industry:
N-METHYL-2-NITROBENZYLAMINE is used as a reactant for the synthesis of biologically active molecules for various applications in the pharmaceutical industry. Its versatility in chemical reactions allows for the creation of a wide range of therapeutic agents.
Used in the Synthesis of Calmodulin Kinase II Inhibitors:
N-METHYL-2-NITROBENZYLAMINE is used as a reactant for the synthesis of Calmodulin Kinase II inhibitors, which are important for the treatment of various neurological disorders and conditions related to calcium signaling.
Used in the Synthesis of AP2238 Derivatives:
N-METHYL-2-NITROBENZYLAMINE is used as a reactant in the synthesis of AP2238 derivatives, which are potential therapeutic agents for the treatment of cancer and other diseases.
Used in the Synthesis of Cholinesterase Inhibitors:
N-METHYL-2-NITROBENZYLAMINE is used as a reactant for the synthesis of Cholinesterase inhibitors, which are essential in the treatment of Alzheimer's disease and other cognitive disorders.
Used in the Synthesis of Azole Antifungal Agents:
N-METHYL-2-NITROBENZYLAMINE is used as a reactant in the synthesis of Azole antifungal agents, which are widely used in the treatment of fungal infections.

InChI:InChI=1/C8H10N2O2/c1-9-6-7-4-2-3-5-8(7)10(11)12/h2-5,9H,6H2,1H3

Upstream product

• 57707-11-6 N-(2-nitrobenzylidene)methanamine 
• 74-89-5 methylamine 
• 552-89-6 2-nitro-benzaldehyde 
• 612-25-9 2-Nitrobenzyl alcohol 
• 163915-96-6 (2-nitrophenyl)methyl methanesulfonate 
• 593-51-1 methylamine hydrochloride 
• 88-72-2 1-methyl-2-nitrobenzene 
• 619-23-8 3-Nitrobenzyl chloride 
• 612-23-7 2-nitrobenzyl chloride 
• 506-68-3 bromocyane 
• 854392-96-4 (2-iodo-benzyl)-methyl-(2-nitro-benzyl)-amine 

Downstream Products

• 1904-69-4 2-amino-N-methylbenzylamine 
• 65514-97-8 N-(2-Aminobenzyl)-2-(methylamino)-1-phenyl-1-ethanol 
• 24526-64-5 nomifensine 
• 85660-33-9 N-(2-Nitrobenzyl)-2-(methylamino)-1-phenyl-1-ethanol 
• 128739-13-9 2--4-methoxyacetophenone 
• 102436-71-5 2--4'-isopropylacetophenone 
• 102436-67-9 2-acetophenone 
• 102436-66-8 2--4'-methylacetophenone 
• 102436-69-1 2--(4'-chloroacetophenone) 
• 98159-53-6 2--4'-fluoroacetophenone 
• 112781-03-0 3-[Methyl-(2-nitro-benzyl)-amino]-1-phenyl-propan-1-one 
• 56222-16-3 N-Methyl-N-cyanomethyl-o-nitro-benzylamin 
• 56222-12-9 N-(2-Methylaminomethyl-phenyl)-hydroxylamine 
• 363138-96-9 (E)-2-[Methyl-(2-nitro-benzyl)-amino]-but-2-enedioic acid dimethyl ester 

Relevant academic research and scientific papers

Facile synthesis of 4-substituted 1,2,4,5-tetrahydro-1,4-benzodiazepin-3-ones by reductive cyclization of 2-chloro-N-(2-nitrobenzyl)acetamides

A facile and efficient method was developed for the synthesis of 1,2,4,5-tetrahydro-1,4-benzodiazepine-3-ones from 2-chloro-N-(2-nitrobenzyl)acetamides through a reductive cyclization using iron-ammonium chloride in ethanol–water in good yields. This method provides a simple approach to these benzodiazepine-3-ones which are of high value in the field of medicinal chemistry research.

GLUCURONIDE PRODRUGS OF TOFACITINIB

The invention relates to glucuronide prodrug compounds of the Janus kinase (JAK) inhibitor tofacitinib having formula (I): (Formula (I)) where A1 and R1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.

GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS

The invention relates to glucuronide prodrug compounds of Janus kinase (JAK) inhibitors having formula I: where W1, R1 and A1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.

Structure-activity relationship of the cinnamamide family of antibiotic potentiators for methicillin-resistant: Staphylococcus aureus (MRSA)

Methicillin-resistant Staphylococcus aureus (MRSA) is a global public health threat. MRSA has evolved a complex set of biochemical processes that mobilize the organism for inducible resistance on challenge by β-lactam antibiotics. Interfering pharmacologi

Stable and Rapid Thiol Bioconjugation by Light-Triggered Thiomaleimide Ring Hydrolysis

Maleimide-mediated thiol-specific derivatization of biomolecules is one of the most efficacious bioconjugation approaches currently available. Alarmingly, however, recent work demonstrates that the resulting thiomaleimide conjugates are susceptible to breakdown via thiol exchange reactions. Herein, we report a new class of maleimides, namely o-CH2NHiPr phenyl maleimides, that undergo unprecedentedly rapid ring hydrolysis after thiol conjugation to form stable thiol exchange-resistant conjugates. Furthermore, we overcome the problem of low shelf lives of maleimide reagents owing to their propensity to undergo ring hydrolysis prior to bioconjugation by developing a photocaged version of this scaffold that resists ring hydrolysis. UV irradiation of thiol bioconjugates formed with this photocaged maleimide unleashes rapid thiomaleimide ring hydrolysis to yield the desired stable conjugates within 1 h under gentle, ice-cold conditions.

Novel chiral bis-phosphoramides as organocatalysts for tetrachlorosilane-mediated reactions

The formation of novel chiral bidentate phosphoroamides structures able to promote Lewis base-catalyzed Lewis acid-mediated reactions was investigated. Two different classes of phosphoroamides were synthetized: the first class presents a phthalic acid/pri

Quinazolinones, Quinazolinthiones, and Quinazolinimines as Nitric Oxide Synthase Inhibitors: Synthetic Study and Biological Evaluation

The synthesis of different compounds with a quinazolinone, quinazolinthione, or quinazolinimine skeleton and their in vitro biological evaluation as inhibitors of inducible and neuronal nitric oxide synthase (iNOS and nNOS) isoforms are described. These d

Sustainable synthesis of diverse privileged heterocycles by palladium-catalyzed aerobic oxidative isocyanide insertion

Heterocycles containing a guanidine moiety are of great importance in medicinal chemistry (Scheme 1).[1] As a result, several methods for the synthesis of these "privileged scaffolds" have been reported.[2, 3] Classical approaches, such as the addition of diamines to isothiocyanates followed by condensation and the coupling of diamines with cyanogen bromide,[2, 4] have some clear limitations, such as the availability and toxicity of reagents. Moreover, these procedures suffer from poor atom and/or step efficiency, thus making them unattractive from a sustainability point of view.

Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[ω-(benzylmethylamino)alkoxy]xanthen-9-ones

In this work, we further investigated a previously introduced class of cholinesterase inhibitors. The removal of the carbamic function from the lead compound xanthostigmine led to a reversible cholinesterase inhibitors 3. Some new 3-[ω-(benzylmethylamino)alkoxy]xanthen-9-one analogs were designed, synthesized, and evaluated for their inhibitory activity against both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). The length of the alkoxy chain of compound 3 was increased and different substituents were introduced. From the IC50 values, it clearly appears that the carbamic residue is crucial to obtain highly potent AChE inhibitors. On the other hand, peculiarity of these compounds is the high selectivity toward BuChE with respect to AChE, being compound 12 the most selective one (6000-fold). The development of selective BuChE inhibitors may be of great interest to clarify the physiological role of this enzyme and to provide novel therapeutics for various diseases.

One-pot synthesis and hydroxylaminolysis of asymmetrical acyclic nitrones

Aromatic aldehydes 1 were reductively aminated to the corresponding secondary amines 2 using NaBH4 in methanol in good yields. Amines 2 were oxidized with H2O2-WO42- regioselectively to nitrones 3, the structures of which were easily determined by reacting them with hydroxylamine hydrochloride as well as by spectral means. The products of hydroxylaminolysis in ether proved to be the corresponding benzaldehyde oximes 4 and benzyl or methyl hydroxylamine hydrochlorides 5. Copyright Taylor & Francis, Inc.